Related Experiment Videos

Role of E2F-1 in chemosensitivity

D Banerjee1, B Schnieders, J Z Fu

  • 1Molecular Pharmacology and Experimental Therapeutics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.

Cancer Research
|October 10, 1998
PubMed

Insights

Overexpressing E2F-1 in fibrosarcoma cells accelerated growth and altered chemosensitivity. E2F-1 increased resistance to 5-fluorouracil but enhanced sensitivity to etoposide and doxorubicin.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • The E2F family of transcription factors, with DP proteins, regulates genes essential for DNA synthesis.
  • Key cancer drug targets like thymidylate synthase (TS) and dihydrofolate reductase are among these genes.
  • Understanding E2F-1's role is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the impact of human E2F-1 cDNA overexpression on chemosensitivity.
  • To analyze the effects on cell proliferation and drug response in HT-1080 fibrosarcoma cells.

Main Methods:

  • Overexpression of human E2F-1 cDNA in HT-1080 fibrosarcoma cells.
  • Assessment of cell doubling time in vitro and in vivo.
  • Evaluation of chemosensitivity to various chemotherapeutic agents.

Main Results:

  • E2F-1 overexpression led to a reduced doubling time for HT-1080 cells.
  • Up-regulation of thymidylate synthase (TS) was observed in E2F-1 transfected cells.
  • Cells overexpressing E2F-1 showed increased resistance to 5-fluorouracil but enhanced sensitivity to etoposide, doxorubicin, and SN38, while remaining unaffected by Taxol.

Conclusions:

  • E2F-1 overexpression influences cell proliferation and alters chemosensitivity profiles.
  • The findings suggest a complex role for E2F-1 in mediating responses to different chemotherapeutic drugs.
  • Targeting E2F-1 pathways may offer novel strategies for cancer treatment, depending on the drug regimen.

Related Concept Videos